The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by McDougle, C. J.
* Articles by Vitiello, B.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by McDougle, C. J.
* Articles by Vitiello, B.
Related Collections
* Autism
* Atypical Neuroleptics
Am J Psychiatry 162:1142-1148, June 2005
© 2005 American Psychiatric Association

Risperidone for the Core Symptom Domains of Autism: Results From the Study by the Autism Network of the Research Units on Pediatric Psychopharmacology

Christopher J. McDougle, M.D., Lawrence Scahill, M.S.N., Ph.D., Michael G. Aman, Ph.D., James T. McCracken, M.D., Elaine Tierney, M.D., Mark Davies, M.P.H., L. Eugene Arnold, M.D., David J. Posey, M.D., Andrès Martin, M.D., M.P.H., Jaswinder K. Ghuman, M.D., Bhavik Shah, M.D., Shirley Z. Chuang, M.S., Naomi B. Swiezy, Ph.D., Nilda M. Gonzalez, M.D., Jill Hollway, B.A., Kathleen Koenig, M.S.N., James J. McGough, M.D., Louise Ritz, M.B.A., and Benedetto Vitiello, M.D.

OBJECTIVE: Risperidone has been found efficacious for decreasing severe tantrums, aggression, and self-injurious behavior in children and adolescents with autistic disorder (autism). The authors report on whether risperidone improves the core symptoms of autism, social and communication impairment and repetitive and stereotyped behavior. METHOD: The database from an 8-week double-blind, placebo-controlled trial (N=101) and 16-week open-label continuation study (N=63) of risperidone for children and adolescents with autism was used to test for drug effects on secondary outcome measures: scores on the Ritvo-Freeman Real Life Rating Scale, the Children’s Yale-Brown Obsessive Compulsive Scale, and the maladaptive behavior domain of the Vineland Adaptive Behavior Scales. RESULTS: Compared to placebo, risperidone led to a significantly greater reduction in the overall score on the Ritvo-Freeman Real Life Rating Scale, as well as the scores on the subscales for sensory motor behaviors (subscale I), affectual reactions (subscale III), and sensory responses (subscale IV). No statistically significant difference was observed, however, on the subscale for social relatedness (subscale II) or language (subscale V). Risperidone also resulted in significantly greater reductions in scores on the Children’s Yale-Brown Obsessive Compulsive Scale and Vineland maladaptive behavior domain. This pattern of treatment response was maintained for 6 months. CONCLUSIONS: Risperidone led to significant improvements in the restricted, repetitive, and stereotyped patterns of behavior, interests, and activities of autistic children but did not significantly change their deficit in social interaction and communication. Further research is necessary to develop effective treatments for the core social and communicative impairments of autism.




This article has been cited by other articles:


Home page
FocusHome page
Bibliography for Child and Adolescent Psychiatry
Focus, June 1, 2008; 6(3): 314 - 316.
[Full Text] [PDF]


Home page
FocusHome page
Abstracts: Child and Adolescent Psychiatry
Focus, June 1, 2008; 6(3): 317 - 321.
[Full Text] [PDF]


Home page
PediatricsHome page
S. M. Myers, C. P. Johnson, and the Council on Children With Disabilities
Management of Children With Autism Spectrum Disorders
Pediatrics, November 1, 2007; 120(5): 1162 - 1182.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
A. de Bildt, E. J. Mulder, T. Scheers, R. B. Minderaa, and H. Tobi
Pervasive Developmental Disorder, Behavior Problems, and Psychotropic Drug Use in Children and Adolescents With Mental Retardation
Pediatrics, December 1, 2006; 118(6): e1860 - e1866.
[Abstract] [Full Text] [PDF]


Home page
Arch Gen PsychiatryHome page
M. Olfson, C. Blanco, L. Liu, C. Moreno, and G. Laje
National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.
Arch Gen Psychiatry, June 1, 2006; 63(6): 679 - 685.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
B. Chavez, M. Chavez-Brown, and J. A Rey
Role of Risperidone in Children with Autism Spectrum Disorder
Ann. Pharmacother., May 1, 2006; 40(5): 909 - 916.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
B. ADETUNJI, M. MATHEWS, T. OSINOWO, and A. WILLIAMS
Risperidone for the Core Symptom Domains of Autism
Am J Psychiatry, March 1, 2006; 163(3): 551 - 551.
[Full Text] [PDF]


Home page
Evid. Based Ment. HealthHome page
E. Fombonne
Risperidone improves restricted, repetitive, and stereotyped behaviour in autistic children and adolescents
Evid. Based Ment. Health, February 1, 2006; 9(1): 6 - 6.
[Full Text] [PDF]


Home page
JWatch PsychiatryHome page
Risperidone May Help Some -- But Not All -- Symptoms of Autism
Journal Watch Psychiatry, July 21, 2005; 2005(721): 4 - 4.
[Full Text]




Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org